Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Core Insights - Werewolf Therapeutics is advancing its clinical trials for WTX-124 and WTX-330, with significant milestones expected in 2025, including interim data readouts and FDA engagement [1][2][5] Clinical Development - WTX-124 is a conditionally activated Interleukin-2 (IL-2) INDUKINE molecule, currently in a Phase 1/1b clinical trial for cutaneous melanoma and renal cell carcinoma, with interim data expected in Q4 2025 [1][5] - WTX-330, an Interleukin-12 (IL-12) INDUKINE molecule, is in a Phase 1b/2 clinical trial for advanced solid tumors, with dosing regimen determination anticipated by the end of 2025 [1][5] - The company has introduced WTX-1011, its first INDUCER T-cell engager targeting STEAP1 for prostate cancer, which has shown promising preclinical data [2][5] Financial Performance - As of June 30, 2025, the company reported cash and cash equivalents of $77.6 million, down from $92.0 million as of March 31, 2025, indicating a need for careful cash management [11][15] - Research and development expenses for Q2 2025 were $13.1 million, a decrease from $15.3 million in Q2 2024, while general and administrative expenses also saw a decline [11][14] - The net loss for Q2 2025 was $18.0 million, slightly higher than the $17.2 million loss reported in the same period of 2024 [11][14]